Effects of oat bran on heart disease patients' cholesterol and gut bacteria
Effect of Oat Bran Supplementation on Plasma Lipid, Selected Fecal Bacteria, and Short-chain Fatty Acids Receptors Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Coronary Artery Disease
This study is testing if eating oat bran can help lower cholesterol and improve gut bacteria in people with heart disease who have just had a procedure to open their arteries.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 32 (estimated) |
| Ages | 40 Years to 75 Years |
| Sex | All |
| Sponsor | Shahid Beheshti University of Medical Sciences Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Tehran and 1 other locations) |
| Trial ID | NCT06747234 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of oat bran on plasma lipid levels and fecal bacteria in patients with coronary artery disease (CAD) who have recently undergone coronary angioplasty. It focuses on the relationship between endotoxemia, low-grade inflammation, and atherosclerosis, aiming to understand how dietary fiber may mitigate these effects. Participants will be divided into an oat bran group and a control group receiving standard treatment to assess changes in their lipid profiles and gut microbiota. The study seeks to provide insights into dietary interventions that could improve cardiovascular health.
Who should consider this trial
Good fit: Ideal candidates are patients with a history of coronary heart disease who have recently undergone coronary angioplasty.
Not a fit: Patients with end-stage renal disease, inflammatory bowel syndrome, or those undergoing recent glucocorticoid or antibiotic treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to dietary recommendations that help reduce inflammation and improve heart health in CAD patients.
How similar studies have performed: While the specific approach of using oat bran in this context may be novel, dietary fiber's role in improving cardiovascular health has been supported by other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a history of coronary heart disease who have recently undergone coronary angioplasty Exclusion Criteria: * End-stage renal disease * Inflammatory bowel syndrome (IBD), * Recent glucocorticoid or antibiotic treatment, * Cancer undergoing chemotherapy or radiotherapy, * Any alteration to the treatment plan, including changes in drug type or surgical intervention
Where this trial is running
Tehran and 1 other locations
- Shahid Modaress Hospital — Tehran, Iran, Islamic Republic of (Recruiting)
- Shahid Modarres Hospital — Tehran, Iran, Islamic Republic of (Not_yet_recruiting)
Study contacts
- Study coordinator: Sogand Tavakoli, Ph.D.
- Email: tavakoli.sgd@gmail.com
- Phone: +989121792248
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.